Cantel Medical Subsidiary - MEDIVATORS ENDOCUFF™ Overtube Improves Adenoma and Polyp Detection

MINNEAPOLIS, Sept. 10, 2014 /PRNewswire/ -- The ENDOCUFF™ Endoscopic Overtube now provided by MEDIVATORS, a leading medical device company with over thirty years of experience in endoscopy technology, substantially improves adenoma and polyp detection during colonoscopies according to two separate industry studies. The ENDOCUFF device is a small disposable plastic over-tube with soft flexible projections. Placed over the tip of the endoscope, the device helps increase control and flatten colonic folds to improve mucosa examination.

With use of the ENDOCUFF device, the number of adenomas detected per patient increased by 86% compared to standard colonoscopy without an endoscopic overtube, stated a 2014 German study published in the Journal of Clinical Gastroenterology. The number of polyps detected per patient was 63% higher with notable superior detection in the sigmoid and cecum regions. Study results were reported at the 2014 Digestive Diseases Week in Chicago, one of the largest annual medical conferences for specialists in gastroenterology.

"The ENDOCUFF device has proven to significantly enhance the physician's ability to visualize and examine the mucosa," said Jorgen Hansen, President of MEDIVATORS.  "This is crucial to achieving our goal of improving screening and saving lives," he stated.

According to the American Cancer Society, colorectal cancer is the second leading cause of cancer-related deaths in the United States and is expected to cause about 50,310 deaths during 2014.  Screening reduces mortality both by decreasing incidence and by detecting cancers at earlier, more treatable stages. It has been estimated that colonoscopy screening has the potential to prevent about 65 percent of colorectal cancer cases.

The ENDOCUFF device study was a randomized prospective two-center trial with a total of 498 patients. Similar results were reported in a 2014 U.S. multi-center study published in Gastrointestinal Endoscopy that retroactively analyzed 318 patients at a tertiary care medical center. An additional study conducted by the New York University School of Medicine to determine the operator learning curve for the ENDOCUFF device found that adenoma detection rate significantly increased with operator experience after only four procedures. 

Hansen added that physicians are reporting the device also assists operators in complex polyp removal. "The ENDOCUFF device reduces slippage and acts as a 'handbrake' during EMR and polypectomy. This helps the physician maintain a steady view during complicated procedures while instruments are fed through the biopsy channel," he explained.

The ENDOCUFF device is radio opaque, disposable, and does not include latex. It is available in multiple sizes to fit most OLYMPUS, PENTAX and FUJINON colonoscopes. The ENDOCUFF™ Endoscopic Overtube is a registered trademark of Arc Medical Design.

About MEDIVATORS

MEDIVATORS, a wholly owned subsidiary of Cantel Medical Corp. (NYSE: CMN), is a leading provider of infection control products and services that ensure the safe and proper disinfection of flexible endoscopes and other devices. Beyond the full line of Medivators ® medical device reprocessing systems, disinfectants, detergents and other supplies for endoscopy, Medivators also provides sterilants, dialysate concentrates and other supplies for renal dialysis, hollow fiber membrane filtration and separation technologies for medical and non medical applications and liquid chemical germicides and decontamination products and services used in other applications for infection prevention and control.

For further information visit the Medivators website at www.medivators.com.

About Cantel Medical Corp.

Cantel Medical (NYSE: CMN) is a leading global company dedicated to delivering innovative infection prevention and control products and services for patients, caregivers, and other healthcare providers which improve outcomes, enhance safety and help save lives.  Our products include specialized medical device reprocessing systems for endoscopy and renal dialysis, advanced water purification equipment, sterilants, disinfectants and cleaners, sterility assurance monitoring products for hospitals and dental clinics, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates, hollow fiber membrane filtration and separation products, and specialty packaging for infectious and biological specimens. Additionally, we provide technical service for our products. 

For further information, visit the Cantel website at www.cantelmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

SOURCE Cantel Medical Corp.